Some checkpoint-related genes (BTLA, CD80, CD86, CTLA4, IDO1, PDCD1LG2, and TIGIT) had decreased expression in the KRAS-mutated group, providing potential opportunities for immunotherapy in colon cancer. This evidence concerns the gene KRAS and malignant colon neoplasm.